Back to Research Hub
Viridian Therapeutics, Inc.
VRDN
$19.17-0.01 (-0.05%)
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED).
StreetsValue research for Viridian Therapeutics, Inc. (VRDN)
Members get the full report for Viridian Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.